A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients
Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service
First received: November 2, 1999
Last updated: June 23, 2005
Last Verified: July 1997
History of Changes
To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.
Drug : Saquinavir
Drug : Lamivudine
Drug : Zidovudine
Primary Purpose: Treatment
|Official Title:||A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients|
Further study details as provided by NIH AIDS Clinical Trials Information Service:
A total of 30 patients receive the triple drug regimen saquinavir plus zidovudine plus lamivudine until the completion of the analysis after at least 4 weeks of therapy.Eligibility
|Ages Eligible for Study:||18 Years and older|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Patients must have:
- HIV antibody positive.
- CD4 count >= 150 and <= 500 cells/mm3.
- Prior antiretroviral therapy.
- Prior protease inhibitor therapy.
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002190
Locations Show More
|United States, California|
|Davies Med Ctr / c/o HIV Institute|
|San Francisco, California, United States, 94114|
|Pacific Oaks Med Group / Rsch & Scientific Investigation|
|Sherman Oaks, California, United States, 91403|
|United States, New York|
|Columbia Presbyterian Med Ctr|
|New York, New York, United States, 10032|
Sponsors and CollaboratorsHoffmann-La Roche
|Responsible Party:||Hoffmann-La Roche|
|ClinicalTrials.gov Identifier:||NCT00002190 History of Changes|
|Other Study ID Numbers:||229N|
|Study First Received:||November 2, 1999|
|Last Updated:||June 23, 2005|
Keywords provided by NIH AIDS Clinical Trials Information Service:Drug Therapy, Combination
HIV Protease Inhibitors
Reverse Transcriptase Inhibitors
Additional relevant MeSH terms:
ClinicalTrials.gov processed this data on October 15, 2019
This information is provided by ClinicalTrials.gov.